180 Life Sciences Corp. (ATNF): Price and Financial Metrics
ATNF Price/Volume Stats
Current price | $2.35 | 52-week high | $51.30 |
Prev. close | $2.01 | 52-week low | $1.80 |
Day low | $1.95 | Volume | 556,037 |
Day high | $3.00 | Avg. volume | 113,548 |
50-day MA | $3.61 | Dividend yield | N/A |
200-day MA | $9.47 | Market Cap | 923.55K |
ATNF Stock Price Chart Interactive Chart >
180 Life Sciences Corp. (ATNF) Company Bio
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and Anti-TNF platform, which focuses on fibrosis and anti-tumor necrosis factors; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Menlo Park, California.
Latest ATNF News From Around the Web
Below are the latest news stories about 180 LIFE SCIENCES CORP that investors may wish to consider to help them evaluate ATNF as an investment opportunity.
180 Life Sciences Engages Financial Advisor to Explore Strategic AlternativesPALO ALTO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced it has engaged A.G.P./Alliance Global Partners as financial advisor to explore and evaluate strategic alternatives to enhance shareholder value. Potential strategic alternatives that may be explored or evaluated by the Company as part of this process include, but are not limited to, an acquisition, merger, reverse merger, other business combination, |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayPre-market stock movers are a good way to start the day as we dive into the biggest news worth checking out on Wednesday morning! |
180 Life Sciences Announces Review of Strategic AlternativesPALO ALTO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that its Board of Directors has initiated a process to evaluate potential strategic alternatives with the intent to unlock and maximize shareholder value. In consultation with financial and legal advisors, the Company intends to consider a broad range of strategic, operational and financial alternatives, and is exploring a full range of options. Ther |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayWe're starting off Thursday with a breakdown of the biggest pre-market stock movers traders need to know about this morning! |
180 Life Sciences Corp. Announces Closing of $3 Million Public OfferingPALO ALTO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the closing of its previously announced public offering of 4,615,385 shares of the Company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 4,615,385 shares of common stock at a purchase price per share (and accompanying warrant) of $0.65. The warrants are immediately e |
ATNF Price Returns
1-mo | -36.57% |
3-mo | -42.07% |
6-mo | -79.81% |
1-year | -93.17% |
3-year | -99.91% |
5-year | N/A |
YTD | -42.07% |
2023 | -93.70% |
2022 | -95.65% |
2021 | 42.86% |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...